| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 1g | |||
| Other Sizes |
| ln Vitro |
Jionoside A1 displayed dose-dependent immune-enhancement activity on 5-fluorouracil (5-FU) induced bone marrow cells, as measured by the CCK-8 proliferation assay. [1]
At a concentration of 50 µM, Jionoside A1 promoted the proliferation of suspended hematopoietic stem cells (HSC) in primary mouse bone marrow cell cultures, as observed morphologically. [1] Jionoside A1 (at 50 µM) showed a noticeable pre-protective capacity against H₂O₂-induced oxidative injury in human neuroblastoma SH-SY5Y cells, increasing cell viability. [1] The pre-protective activity of Jionoside A1 against H₂O₂ injury in SH-SY5Y cells was reported for the first time in this study. [1] |
|---|---|
| Cell Assay |
Bone Marrow Cell Immune-Enhancement Assay: Specific pathogen-free, 5-6 week old female BALB/C mice were intraperitoneally injected with 5-fluorouracil (5-FU, 200 mg/kg body weight). Two days later, mice were sacrificed, and primary bone marrow cell suspensions were prepared. Cells were plated in 6-well plates at a density of 3.5 × 10⁵ cells per well in culture medium (DMEM with 10% FBS, 1% penicillin/streptomycin) containing 50 µM Jionoside A1. Cells were incubated at 37°C with 5% CO₂. Half of the supernatant was replaced weekly with fresh medium containing the compound. Cell growth was observed under an inverted microscope for four weeks. For dose-dependence evaluation, bone marrow stem cells were seeded in 96-well plates (1000 cells/well) and cultured with different concentrations of Jionoside A1 (0, 0.1, 1, 10, 25, 50 µM). Cell proliferation was assessed on day 3 or 6 using the CCK-8 colorimetric assay, measuring absorbance at 450 nm. [1]
SH-SY5Y Cell Oxidative Injury Protection Assay: Human neuroblastoma SH-SY5Y cells were seeded in 96-well plates at a density of 5 × 10² cells per well and allowed to adhere for 24 hours. Cells were pre-incubated with Jionoside A1 (tested at 10 µM and 50 µM) for 12 hours. Then, each well was treated with 100 µL of 800 µM H₂O₂ for 3 hours. Afterward, MTT solution was added and incubated for 4 hours. The medium was discarded, 100 µL DMSO was added to each well, and the absorbance was measured at 550 nm. Cell viability was calculated based on three replicate wells. [1] bEnd.3 Cell Oxidative Injury Protection Assay: Mouse microvascular endothelial cells (bEnd.3) were seeded into 96-well plates at 5 × 10² cells per well and allowed to adhere for 24 hours. Then, 10 µL of a compound solution (final concentration 50 µM) was added and co-incubated for 24 hours to evaluate potential cytotoxicity using the MTT assay. For the protection assay, cells were pre-treated with the compound (50 µM) for 12 hours, then impaired with 850 µM H₂O₂ for 3 hours. Cell viability was assessed using the MTT assay as described. [1] |
| References | |
| Additional Infomation |
It has been reported that Cistanche tubulosa and Cistanche phelypaea contain gianoside A1, and there are related data reports.
Gianoside A1 was isolated from Radix Rehmanniae Praeparata. [1] It has been identified as one of the chemical components of compound donkey-hide gelatin (FES), a traditional Chinese medicine preparation. [1] It has been reported that phenylethanoid glycosides (including gianoside A1) in Radix Rehmanniae Praeparata play an important role in enhancing immunity. [1] |
| Molecular Formula |
C36H48O20
|
|---|---|
| Molecular Weight |
800.7543
|
| Exact Mass |
800.273
|
| CAS # |
120444-60-2
|
| PubChem CID |
6325450
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.61±0.1 g/cm3(Predicted)
|
| Boiling Point |
1039.4±65.0 °C(Predicted)
|
| LogP |
-1.8
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
20
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
56
|
| Complexity |
1250
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
O([C@@]1([H])[C@@]([H])([C@@]([H])([C@]([H])([C@]([H])(C([H])([H])[H])O1)O[H])O[H])O[H])[C@]1([H])[C@]([H])([C@]([H])(OC([H])([H])C([H])([H])C2C([H])=C([H])C(=C(C=2[H])O[H])O[H])O[C@]([H])(C([H])([H])O[C@@]2([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O2)O[H])O[H])O[H])[C@@]1([H])OC(/C(/[H])=C(\[H])/C1C([H])=C([H])C(=C(C=1[H])OC([H])([H])[H])O[H])=O)O[H]
|
| InChi Key |
UAPZTGRENZINFN-WEDRDYHSSA-N
|
| InChi Code |
InChI=1S/C36H48O20/c1-15-25(42)27(44)30(47)36(52-15)56-33-31(48)35(50-10-9-17-3-6-18(38)20(40)11-17)54-23(14-51-34-29(46)28(45)26(43)22(13-37)53-34)32(33)55-24(41)8-5-16-4-7-19(39)21(12-16)49-2/h3-8,11-12,15,22-23,25-40,42-48H,9-10,13-14H2,1-2H3/b8-5+/t15-,22+,23+,25-,26+,27+,28-,29+,30+,31+,32+,33+,34+,35+,36-/m0/s1
|
| Chemical Name |
[(2R,3R,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2488 mL | 6.2441 mL | 12.4883 mL | |
| 5 mM | 0.2498 mL | 1.2488 mL | 2.4977 mL | |
| 10 mM | 0.1249 mL | 0.6244 mL | 1.2488 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
